Yes that's right, FDA clearance for iTrack Advance is expected next week (by the end of the month at most), which should be transformative for the company and result in a significant acceleration in revenue.
No problem, like I said the LEAD trial outcome was likely due to having patients with RPD contaminating the study (tech has improved since the LEAD trial and we can now easily identify patients with RPD and therefore exclude them from receiving treatment). The sub analysis of the LEAD trial showed significant evidence that 2RT is extremely effective in almost completely halting progression of AMD in patients without RPD (the vast majority) and therefore there is compelling evidence to conduct I final validation study in order to gain FDA approval for that.
In the meantime, I would only consider iTrack Advance in assessments and the valuation of the company (given that the market is also not considering 2RT in its valuation of the company. 2RT would be the cherry on top, but is not at all an essential part of EYE's future potential
Nova Eye Medical (EYE) Discussion, page-36
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.005(1.96%) |
Mkt cap ! $59.49M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.0¢ | 25.0¢ | $41.12K | 162.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21139 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 57200 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.005 ( 1.96 %) |
||||
| Open | High | Low | Volume | ||
| 26.5¢ | 26.5¢ | 25.0¢ | 37040 | ||
| Last updated 15.17pm 15/05/2024 ? | |||||
| EYE (ASX) Chart |